Preclinical research showed that YM155 can effectively decrease survivin expression levels in various cancer cell lines and inhibit tumor growth in xenografts mouse models, including prostate cancer, non-Hodgkin lymphoma, and lung cancer [127,128]. Here, BIRC5 is linked to neoplasm.